Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.32 |
| ▸ | HTR7 | P34969 | 4/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26811513 | 0.91 | AURKA (0.36) | HTR1AHTR7FGFR1FGFR3AURKA | |
| SCHEMBL26811495 | 0.89 | PARP1 (0.34) | PARP1HTR1AHTR7HRH3FGFR1 | |
| SCHEMBL26811516 | 0.88 | FGFR1 (0.36) | HTR1AHTR7FGFR1FGFR3 | |
| SCHEMBL24310605 | 0.82 | NMT1 (0.35) | HTR1AHTR7AURKAAURKBDRD2 | |
| SCHEMBL29566526 | 0.82 | NMT1 (0.35) | HTR1AHTR7AURKAAURKBDRD2 | |
| SCHEMBL26811433 | 0.82 | HSD11B1 (0.35) | HTR1AHTR7 | |
| SCHEMBL24310022 | 0.81 | EGFR (0.35) | HTR1AHTR7DRD2HTR6 | |
| SCHEMBL29567020 | 0.81 | HTR1A (0.34) | HTR1AHTR7DRD2HTR6 | |
| SCHEMBL24310616 | 0.81 | HTR1A (0.34) | HTR1AHTR7DRD2HTR6 | |
| SCHEMBL24309774 | 0.81 | HTR1A (0.34) | HTR1AHTR7HRH3FGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PARP1 4715/4885HTR1A 4018/4885HTR7 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.